Business, energy, technology, markets and global industry news from Business News Today

Fbody

Pharma & Biotech

Forlong Biotechnology doses first patient in Australian Phase 1 trial of subcutaneous FL115

Forlong Biotechnology begins Australian Phase 1 testing of subcutaneous FL115, targeting lower peak exposure and improved immune activation.

Read More